Clearwater, Florida, May 24, 2016 (GLOBE NEWSWIRE) -- Acacia Diversified Holdings, Inc. (OTCQB: ACCA) today announced that its new MariJ Pharmaceuticals, Inc. subsidiary has completed its second service agreement with Colorado organic hemp producer CBDRx, extracting CBD-rich medicinal cannabis oils at their facility.

CBDRx announced earlier this year that it has received USDA Organic Certification for its entire hemp crop. As of this date CBDRx is the first company in the U.S. to have the processes, documentation, and transparency necessary to achieve this federal organic certification. MariJ has concentrated its efforts on extracting and providing high-quality cannabis oils from organically grown hemp meeting certain grade specifications.

“MariJ Pharmaceuticals is pleased to have this relationship with such a quality supplier of natural, organic hemp to meet our needs in the industry,” said Rick Pertile, CEO of MariJ and its publicly-traded parent, Acacia Diversified Holdings. “We strive to provide quality services and retail products, and it can only be done when we start with the best going in our extraction methodologies.”

Marc Brannigan, of CBDRx, stated: "The CBD industry is plagued by products from unidentifiable overseas sources making dubious, unverifiable, and false claims. We are understandably proud to be one of the first companies in the United States offering certified organic CBD products with the high quality, consistency, and transparency that this industry demands, and which CBDRx's domestically-grown USDA Certified Organic hemp can deliver. MariJ delivered a high-quality oil extraction from our high quality plants.”

MariJ Pharmaceuticals and its sister unit, Canna-Cures Research & Development Center, Inc., became Acacia subsidiaries effective January 4, 2016 following their acquisition by the public company. Acacia plans to utilize its proprietary “seed to oil” tracking and its “plant to patient” solutions in conjunction with the Canna-Cures R&D unit.

Forward-Looking Statements

Statements in this press release may be "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "anticipate", "believe", "estimate", "expect", "intend" and similar expressions, as they relate to the company or its management, identify forward-looking statements. These statements are based on current expectations, estimates and projections about the company's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may, and probably will, differ materially from what is expressed or forecasted in such forward-looking statements due to numerous factors. Any forward-looking statements speak only as of the date on which they are made, and the Company does not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date of this release. Information on the Acacia or MariJ Pharmaceuticals websites does not constitute a part of this release.

Mr. Richard K. Pertile, CEO MariJ Pharmaceuticals, Inc. (an Acacia Diversified Holdings, Inc. company) 13575 58th Street North - #138 Clearwater, FL 33760 Email: Internet: Office: (727) 678-4420 Fax: (877) 513-6295

Source:Acacia Diversified Holdings, Inc.